Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Heparan Sulfate Proteoglycan (Large) / Perlecan Antibody - With BSA and Azide
Rat Monoclonal Antibody [Clone A7L6 ]
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC, IF, FC |
|---|---|
| Primary Accession | P98160 |
| Other Accession | 3339, 562227 |
| Reactivity | Human, Mouse, Monkey, Pig, Fish, Bovine |
| Host | Rat |
| Clonality | Monoclonal |
| Isotype | Rat / IgG2a, kappa |
| Clone Names | A7L6 |
| Calculated MW | >400kDa |
| Gene ID | 3339 |
|---|---|
| Other Names | Basement membrane-specific heparan sulfate proteoglycan core protein, HSPG, Perlecan, PLC, Endorepellin, LG3 peptide, HSPG2 |
| Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
| Precautions | Heparan Sulfate Proteoglycan (Large) / Perlecan Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | HSPG2 |
|---|---|
| Function | Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It serves as an attachment substrate for cells. Plays essential roles in vascularization. Critical for normal heart development and for regulating the vascular response to injury. Also required for avascular cartilage development. [LG3 peptide]: Has anti-angiogenic properties that require binding of calcium ions for full activity. |
| Cellular Location | Secreted, extracellular space, extracellular matrix, basement membrane. Secreted |
| Tissue Location | Detected in cerebrospinal fluid, fibroblasts and urine (at protein level). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This MAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.
References
Folkvord et. al., J Histochem Cytochem, 1989; 37:105-113. | Couchman et. al., Matrix, 1989; 9:311-321. | Horiguchi et. al., J Histochem Cytochem, 1989; 37:961-970. | Ljubimov et. al., Int J Cancer, 1992; 50:562-566. | Guelstein et. al., Int J Cancer, 1993; 53:269-277. | Ljubimov et. al., Lab Invest, 1995; 72:461-473
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
